SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Guidant (GDT)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Lighthouse who wrote (181)7/17/2001 10:07:21 AM
From: Lighthouse  Read Replies (1) of 235
 
I am sure our friends at GDT saw the Cook news yesterday. Here is a swipe from a "research" house that I agree with.

"Yesterday, Cook Cardiology announced that it had implanted the first paclitaxel-coated coronary stent in its US trial. The implant was done on July 10. While the start of the trial was generally expected, the significance of this announcement to ANPI is that it solidifies Cook's position as the clear #2 player in the drug coated stent race behind JNJ and increases the likelihood of Cook as an M&A target assuming good data.
Full enrollment will include about 800 patients and be completed early in 2002 according to Cook. The trials endpoints will be similar to JNJ's with nine-month follow-up required. While the FDA has not given final approval to enroll all 800, Cook has shown the FDA six-month data on well over 100 patients from outside the US and has answered all of the agencies questions. We believe approval to enroll all 800 will not be an issue."

Cook is in Bloomington, GDT is in Indy.

Cheers,
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News